Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): A phase I study.
Haruko Daga
No relevant relationships to disclose
Koji Takeda
No relevant relationships to disclose
Hideaki Okada
No relevant relationships to disclose
Masaki Miyazaki
No relevant relationships to disclose
Shinya Ueda
No relevant relationships to disclose
Hiroyasu Kaneda
No relevant relationships to disclose
Isamu Okamoto
No relevant relationships to disclose
Kiyotaka Yoh
No relevant relationships to disclose
Koichi Goto
No relevant relationships to disclose
Koichi Konishi
Employment or Leadership Position - Nippon Boehringer Ingelheim
Akiko Sarashina
No relevant relationships to disclose
Nobutaka Yagi
Employment or Leadership Position - Nippon Boehringer Ingelheim
Kiyomi Mera
Employment or Leadership Position - Nippon Boehringer Ingelheim
Rolf Kaiser
Employment or Leadership Position - Boehringer Ingelheim
Kazuhiko Nakagawa
Honoraria - Boehringer Ingelheim; Lilly